MedTrace Logo

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

NCT05054257 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-01-06

No results posted yet for this study

Summary

Phase I Dose Escalation Study of CART19 Cells for Adult Patients With Relapsed / Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma.

Conditions

  • Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma Refractory
  • Non-Hodgkin's Lymphoma, Relapsed

Interventions

DRUG

Autologous CAR19 T lymphocytes

First-in-human trial examining the safety and efficacy of CART19 in r/r B-ALL and B-NHL

Sponsors & Collaborators

  • Institute of Hematology and Blood Transfusion, Czech Republic

    lead OTHER

Principal Investigators

  • Petr Lesny · Institute of Hematology and Blood Transfusion, Czech Republic

  • Jan Vydra · Institute of Hematology and Blood Transfusion, Czech Republic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-02
Primary Completion
2025-06-01
Completion
2025-12-12

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05054257 on ClinicalTrials.gov